Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. - Wikidata - awgldk - TriplyDB

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

http://www.wikidata.org/entity/Q35828771

about

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Infections in myelodysplastic syndromes Myelodysplastic syndromes: what do hospitalists need to know?Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog Myelodysplastic syndromes: the role of the immune system in pathogenesis.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia.Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality.Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment Recognition of tumors by the innate immune system and natural killer cells.Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.Biology of BM failure syndromes: role of microenvironment and niches.Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.Biology of the bone marrow microenvironment and myelodysplastic syndromes.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells NK cell receptors and their ligands in leukemia.Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T Cells Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Immune alterations in untreated and treated myelodysplastic syndrome.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?Natural killer cell immune escape in acute myeloid leukemia.NK cells: key to success of DC-based cancer vaccines?Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

P2860

Q26746104-56A96C90-DE9B-49E8-9C20-81CFA163F1AA Q26751011-4D70085D-ECDC-4D76-8987-22E49F0096C9 Q26859275-618EC9C0-F31C-41E0-BAB0-0BFB5CE5DEAD Q27011372-E516710D-3A3A-4CC1-A9B5-BF58F06D231A Q27015288-8BB52241-F868-45BE-A713-715DDCC45F42 Q28662217-9F8D1354-7E2B-4646-A4D2-C3650AD710D3 Q33351527-26E1AD3B-50AC-41D0-A281-0263FA77C421 Q33397165-FBC81BAD-3198-4137-A11B-62BA78BFB3DE Q33468660-172AD125-E4BC-4813-BAD5-AAC25A2435FC Q33584049-BE81FE0A-BFDF-4C68-982D-68BDB8563552 Q33585293-AE8AF123-9860-44A4-A74A-843E0CB1ABD0 Q33595548-338042CB-923E-4F53-BF09-B1C56C6E0F92 Q33659992-08B54ABA-4ABF-4478-B29F-7039EE9094CD Q34161567-CCF57F36-87F9-436D-B69D-F324C330F599 Q34496462-2943D2AF-3BCF-48C4-81F3-B7EA6C9F273F Q34510880-9B92045F-858A-425E-9864-C558CAE4E8E5 Q35208414-7C3D1F56-65DE-4E56-AF74-AC71A61AEE77 Q35458400-7BB73167-AE1B-4B8B-BD38-F31C1309BBD3 Q35568527-7D300ED2-9477-4238-99AE-6D5540426CCA Q35571031-E0BD95C8-4C07-401D-9667-E0921AE21E8C Q36026855-0FB424EC-9CEF-495C-B11C-7278E76DAEC1 Q36056594-7BB45813-5A88-4057-A19E-D1D0C9452821 Q36201068-9C335860-7AF5-431D-808F-9890837CDD22 Q36498399-A593A201-F829-41AD-9108-B46558F7525F Q36544042-1466F647-F81D-4CEB-B4D1-270FDE15E6EA Q36772346-98C0714C-20CA-4946-9AAC-423598C0C1BA Q36965455-55A2AFDD-2987-4D04-BA12-65A9DEE37080 Q36969858-CCFB096E-CA9E-4A5C-9A00-E6F4895466C8 Q37018656-BF380B1E-5AF4-4EC8-BE77-12B3439038FC Q37146038-134AC748-5521-4BC5-BF78-7D7AFD0D6EE4 Q37303329-CFED8AEC-3910-412D-BA35-5DCBCB64215B Q37317299-1DBF8FD6-3F86-4929-8C27-8CF57200E204 Q37779043-8896054F-4FA5-46F5-9B90-4E8AD44C4B60 Q37854701-5F27A407-DDC5-4618-AD34-0688E2A3DC2A Q37864686-D2C4AC71-47A2-40D7-8F07-AC547E2A1C8E Q37885284-085C06A9-63CC-4DEB-BAE7-75B9DE980432 Q37980495-6DA1F02B-DF5D-49D1-8CD0-50CBB7CB5D38 Q37996816-C67865DE-07D4-449C-A679-1522E69EB7AB Q38036202-E913003A-2210-4FA1-823B-F62FF228CBA1 Q38037118-E52D2A6A-720F-4FC7-931B-99C42DEC95EB

P2860

Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

http://www.wikidata.org/entity/Q35828771

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@ast

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@en

type

label

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@ast

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@en

prefLabel

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@ast

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@en

P1433

Q35828771-9A1A84E4-3363-49D3-907F-F628D413E7C1

P1476

Q35828771-95E0C437-F2C4-4C80-9529-FB09A1D91CC7

P2093

Q35828771-1701270A-1903-4EEE-984D-47634B45A4AE

Q35828771-173241C5-BCCA-4A6A-8B06-79431429E0D9

Q35828771-1878C2F5-38E4-40E5-9335-5F0E0DA99215

Q35828771-37FE5971-C980-4E75-B112-1B1E1B24D194

Q35828771-58CA6684-3FCD-4072-8229-C296E5C67B44

Q35828771-5B377D95-DD8F-4483-8DB2-4EA3352D4CB6

Q35828771-7431A873-2E79-4326-AC1F-FD7AD1E0F13D

Q35828771-81D2CE8F-0629-4D2F-85A6-56CA1A48722E

Q35828771-8FA1A767-BD3F-45B1-A9DB-2C860404498D

Q35828771-95DC92B6-DFB7-4C04-A2C7-47BF506E42E7

P2860

Q35828771-002449CE-EA6E-4FF0-BD13-933802B4A93B

Q35828771-0722817D-A76A-4E84-8573-1EED244EF55F

Q35828771-13F0E99A-5992-4678-BE24-B6454FF3F072

Q35828771-14917BEC-BB97-4D6E-A47C-DCE206DF9679

Q35828771-14DFE7A4-6B30-4655-AF89-DB021B213A9C

Q35828771-1D5B4AEC-EF08-4F54-822B-80B9127812C0

Q35828771-2104480F-B8D4-43C4-90EA-017B96D5E5C6

Q35828771-3586FFC4-7454-470D-BB62-973267F90F86

Q35828771-3F680905-859D-45EF-82AC-3A882D74A58B

Q35828771-4A26EC25-5218-46D3-B535-D6E749908E83

P304

Q35828771-7056AFCF-A571-4695-BDF3-82340E885684

P31

Q35828771-0EF84B43-CB18-4975-A70C-52B1EAA8911A

P356

Q35828771-EDF0E3BC-F1C4-4BB3-978F-0CC9E6F7639F

P407

Q35828771-89006816-A67E-4C2E-AFF0-A5E77BC697E7

P433

Q35828771-811AEAE5-B02D-488F-8883-B71291E2D20B

P478

Q35828771-7E3EE3C7-ABAB-49A6-8765-C964D71DAF32

P577

Q35828771-586A3B14-4BA0-47BF-9F54-E3BF33E1BFCF

P5875

Q35828771-846000E6-0337-45F7-AD59-0E613BC01BA1

P698

Q35828771-477416AA-60BF-404F-988A-9D9B12AB50FB

P932

Q35828771-5CDED17B-E187-4EA6-B4F9-B4C5CC79E5F5

P356

BLOOD-2006-07-035519

P1433

P1476

Reduced natural killer (NK) fu ...... on of activating NK receptors.

@en

P2093

Alan F List

http://www.w3.org/2001/XMLSchema#string

Bin Zhong

http://www.w3.org/2001/XMLSchema#string

Dana E Rollison

http://www.w3.org/2001/XMLSchema#string

David Boulware

http://www.w3.org/2001/XMLSchema#string

Edna Ku

http://www.w3.org/2001/XMLSchema#string

Fanqi Bai

http://www.w3.org/2001/XMLSchema#string

Helmut R Salih

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Painter

http://www.w3.org/2001/XMLSchema#string

Jianxiang Zou

http://www.w3.org/2001/XMLSchema#string

Julie Y Djeu

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

An activating immunoreceptor complex formed by NKG2D and DAP10

ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells

Regulation of cutaneous malignancy by gammadelta T cells

Selective cross-talk among natural cytotoxicity receptors in human natural killer cells

A view to a kill: signals triggering cytotoxicity

UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells

Syk regulation of phosphoinositide 3-kinase-dependent NK cell function

Myelodysplastic syndromes.

P304

4816-4824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-07-035519

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6464484

http://www.w3.org/2001/XMLSchema#string

P698

17341666

http://www.w3.org/2001/XMLSchema#string

P932

1885518

http://www.w3.org/2001/XMLSchema#string